Are you Dr. Xiao?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 19 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
243 Charles St
Boston, MA 02114Phone+1 617-573-3380Fax+1 617-573-4033
Summary
- Dr. Peng Xiao, MD is a board certified anesthesiologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts, West Virginia, and Pennsylvania. He is affiliated with Massachusetts General Hospital, Massachusetts Eye and Ear, and Tufts Medical Center.
Education & Training
- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Anesthesiology, 1998 - 2001
- Icahn School of Medicine at Mount Sinai (New York Eye and Ear Infirmary at Mount Sinai)Residency, Surgery, 1997 - 1998
- Suzhou Medical CollegeClass of 1982
Certifications & Licensure
- MA State Medical License 2001 - 2025
- WV State Medical License 2001 - 2025
- PA State Medical License 1999 - 2001
- American Board of Anesthesiology Anesthesiology
Publications & Presentations
PubMed
- 85 citationsMiR-422a as a potential cellular microRNA biomarker for postmenopausal osteoporosis.Zheng Cao, Benjamin T. Moore, Yang Wang, Xian Hao Peng, Joan M. Lappe
Plos One. 2014-05-12 - 138 citationsMiR-133a in Human Circulating Monocytes: A Potential Biomarker Associated with Postmenopausal OsteoporosisYang Wang, Ling Li, Benjamin T. Moore, Xian Hao Peng, Xiang Fang
Plos One. 2012-04-10 - 7 citationsImmunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens.Devivasha Bordoloi, Peng Xiao, Hyeree Choi, Michelle Ho, Alfredo Perales-Puchalt
Genes & Cancer. 2021-01-01
Press Mentions
- MBZUAI Welcomes Senior Delegation from Weizmann Institute in Abu DhabiMay 3rd, 2021
- G42 and ONT Co-Develop Ultra-Scalable RNA Sequencing Based Solution for COVID-19 DetectionJune 11th, 2020
- UAE’s Group 42 and UK’s Oxford Nanopore Co-Develop Ultra-Scalable Solution for COVID-19 DetectionJune 9th, 2020
- Join now to see all